Barclays PLC Acquires 178,179 Shares of Sana Biotechnology, Inc. (NASDAQ:SANA)

Barclays PLC grew its holdings in Sana Biotechnology, Inc. (NASDAQ:SANA) by 126.6% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 318,910 shares of the company’s stock after buying an additional 178,179 shares during the period. Barclays PLC owned 0.14% of Sana Biotechnology worth $1,325,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in SANA. FMR LLC grew its stake in Sana Biotechnology by 16.3% in the 3rd quarter. FMR LLC now owns 31,609,175 shares of the company’s stock valued at $131,494,000 after buying an additional 4,438,949 shares during the last quarter. State Street Corp boosted its holdings in shares of Sana Biotechnology by 4.2% during the third quarter. State Street Corp now owns 6,627,320 shares of the company’s stock worth $27,570,000 after acquiring an additional 269,274 shares during the period. Integral Health Asset Management LLC grew its position in shares of Sana Biotechnology by 22.4% in the second quarter. Integral Health Asset Management LLC now owns 1,200,000 shares of the company’s stock valued at $6,552,000 after purchasing an additional 220,000 shares during the last quarter. Charles Schwab Investment Management Inc. increased its stake in shares of Sana Biotechnology by 11.2% during the third quarter. Charles Schwab Investment Management Inc. now owns 1,047,846 shares of the company’s stock worth $4,359,000 after purchasing an additional 105,382 shares during the period. Finally, Squarepoint Ops LLC lifted its holdings in Sana Biotechnology by 318.8% during the 2nd quarter. Squarepoint Ops LLC now owns 126,572 shares of the company’s stock worth $691,000 after purchasing an additional 96,348 shares during the last quarter. 88.23% of the stock is currently owned by institutional investors.

Sana Biotechnology Stock Performance

SANA stock opened at $1.61 on Friday. The company has a market capitalization of $359.46 million, a P/E ratio of -1.15 and a beta of 1.33. Sana Biotechnology, Inc. has a 52-week low of $1.55 and a 52-week high of $12.00. The company has a fifty day moving average price of $2.68 and a 200-day moving average price of $4.30.

Sana Biotechnology (NASDAQ:SANA) last issued its quarterly earnings results on Friday, November 8th. The company reported ($0.25) EPS for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.01. As a group, sell-side analysts forecast that Sana Biotechnology, Inc. will post -1.16 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have issued reports on SANA. JMP Securities lowered shares of Sana Biotechnology from an “outperform” rating to a “market perform” rating in a research report on Tuesday, November 5th. HC Wainwright restated a “buy” rating and issued a $8.00 price target on shares of Sana Biotechnology in a research report on Wednesday, November 27th.

About Sana Biotechnology

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.